Bifidobacterium preparations combined with enteral nutrition for severe acute pancreatitis: a meta-analysis

doi:10.3760/cma.j.cn441417-20241125-14007

Abstract

Abstract:

Objective　To evaluate the efficacy and safety of bifidobacterium preparations and enteral nutrition for severe acute pancreatitis. Methods　China National Knowledge Infrastructure (CNKI), VIP, Wanfang Data, PubMed, and Embase were searched for the clinical trials published from their establishment to June 2024. The RevMan 5.3 software was used for the meta-analysis of the included researches. The Cochrane handbook5.3 was used to evaluate the literature quality. Results　Nineteen randomized controlled trials were included. The meta analysis results showed that there were statistical differences in the levels of C-reactive protein (CRP) (SMD=-3.72, 95%CI -4.67--2.78, Z=7.74, P<0.01), interleukin (IL)-6 (SMD=-2.44, 95%CI -3.38--1.48, Z=5.07, P<0.01), IL-8 (SMD=-2.66, 95%CI -3.68--1.64, Z=5.13, P<0.01), tumor necrosis factor (TNF)-α (SMD=-3.15, 95%CI -3.98--2.33, Z=7.51, P<0.01), white blood cell count (WBC) (SMD=-1.26, 95%CI -1.83--0.69, Z=4.30, P<0.01), amylase (AMY) (SMD=-0.98, 95%CI -1.30--0.66, Z=5.97, P<0.01), diamine oxidase (DAO) (SMD=-3.55, 95%CI -4.61--2.49, Z=6.54, P<0.01), lactic acid (Lac) (SMD=-2.93, 95%CI -3.76--2.10, Z=6.93, P<0.01, and endotoxin (SMD=-2.26, 95%CI -2.83--1.68, Z=7.63, P<0.01) between the two groups. Conclusions　Bifidobacterium preparations combined with enteral nutrition can effectively inhibit the inflammatory response of patients with severe acute pancreatitis, reduce the level of AMY, and promote their recovery.

Key words: Bifidobacterium preparations, , Enteral nutrition, , Severe acute pancreatitis, , Meta-analysis

摘要：

目的　评价双歧杆菌制剂联合肠内营养治疗重症胰腺炎的有效性与安全性。方法　检索知网、维普、万方、PubMed、Embase等数据库，筛选临床试验，时间为建库至2024年6月。采用RevMan 5.3软件对纳入的研究进行meta分析，Cochrane handbook5.3评价纳入文献的质量。结果　共纳入19篇随机对照试验，meta分析结果示：两组C反应蛋白（CRP）（SMD=-3.72，95%CI -4.67～-2.78，Z=7.74，P<0.01）、白细胞介素（IL）-6（SMD=-2.44，95%CI -3.38～-1.48，Z=5.07，P<0.01）、IL-8（SMD=-2.66，95%CI -3.68～-1.64，Z=5.13，P<0.01）、肿瘤坏死因子（TNF）-α（SMD=-3.15，95%CI -3.98～-2.33，Z=7.51，P<0.01）、白细胞计数（WBC）（SMD=-1.26，95%CI -1.83～-0.69，Z=4.30，P<0.01）、淀粉酶（AMY）（SMD=-0.98，95%CI=-1.30～-0.66，Z=5.97，P<0.01）、二胺氧化酶（DAO）（SMD=-3.55，95%CI -4.61～-2.49，Z=6.54，P<0.01）、乳酸（Lac）（SMD=-2.93，95%CI -3.76～-2.10，Z=6.93，P<0.01）、内毒素（SMD=-2.26，95%CI -2.83～-1.68，Z=7.63，P<0.01）比水平较，差异均有统计学意义。结论　双歧杆菌制剂联合肠内营养可以有效抑制重症急性胰腺炎患者的炎症反应，降低患者AMY水平，促进患者恢复。

关键词:

双歧杆菌, 肠内营养, 重症急性胰腺炎, meta分析

Li Yang, Zhou Ze, Liu Jinxiang, Shi Ying, Ma Xiaobing, Jing Zhiqiang.

Bifidobacterium preparations combined with enteral nutrition for severe acute pancreatitis: a meta-analysis [J]. International Medicine and Health Guidance News, 2025, 31(14): 2317-2323.

李洋周泽刘金响史英马小兵荆志强.

双歧杆菌制剂联合肠内营养治疗重症急性胰腺炎效果的meta分析 [J]. 国际医药卫生导报, 2025, 31(14): 2317-2323.

References

[1]Oland GL, Hines OJ. New guidelines for the treatment of severe acute pancreatitis [J]. Hepatobiliary Surg Nutr, 2022, 11(6): 913-916. DOI: 10.21037/hbsn-22-532.

[2]Sohail Z, Shaikh H, Iqbal N, et al. Acute pancreatitis: a narrative review [J]. J Pak Med Assoc, 2024, 74(5): 953-958. DOI: 10.47391/JPMA.9280.

[3]Lin J, Lv C, Wu C, et al. Incidence and risk factors of nasogastric feeding intolerance in moderately-severe to severe acute pancreatitis [J]. BMC Gastroenterol, 2022, 22(1): 327. DOI: 10.1186/s12876-022-02403-w.

[4]Xie J, Cai Y, Xu H, et al. Early enteral nutrition support for patients with acute pancreatitis in the inpatient setting: a best practice implementation project [J]. JBI Evid Implement, 2024, 22(2): 175-185. DOI: 10.1097/XEB.0000000000000410.

[5]陈从林,罗和生.重症急性胰腺炎营养治疗问题浅析[J].胃肠病学和肝病学杂志,2023,32(1):5-8. DOI:10.3969/j.issn.1006-5709.2023.01.002.

[6]Sun JK, Lv C, Gao L, et al. Nutrition therapy in critically ill patients with severe acute pancreatitis [J]. Nutr Clin Pract, 2024, 39(2): 271-280. DOI: 10.1002/ncp.11135.

[7]Zhang H, Li L, Wu J, et al. Enteral nutrition preparations for blood glucose variability and prognosis for severe acute pancreatitis with stress hyperglycemia [J]. Altern Ther Health Med, 2023, 29(1): 163-169.

[8]张琪,赵燕超.奥美拉唑注射液联合肠内营养支持治疗急性胰腺炎患者的效果[J].国际医药卫生导报,2023,29(7):978-982. DOI:10.3760/cma.j.issn.1007-1245. 2023.07.020.

[9]Werawatganon D, Vivatvakin S, Somanawat K, et al. Effects of probiotics on pancreatic inflammation and intestinal integrity in mice with acute pancreatitis [J]. BMC Complement Med Ther, 2023, 23(1): 166. DOI: 10.1186/s12906-023-03998-7.

[10]郭萍,陈建,王化强,等.双歧杆菌三联活菌胶囊联合肠内营养支持在重症急性胰腺炎患者中的应用[J].青岛医药卫生,2022,54(1):24-27. DOI: 10.3969/j.issn.1006-5571. 2022.01.006.

[11]檀心广,梁晓华,杨杨,等.双歧杆菌三联活菌散辅助经鼻空肠营养对SAP患者实验室指标、并发症及经济性的影响[J].河北医药,2016,38(22):3385-3387. DOI:10.3969/j.issn.1002-7386.2016.22.006.

[12]徐振华,李义安.双歧杆菌三联活菌与肠内营养液联用对重症急性胰腺炎患者肠道功能的疗效及其对各炎症因子水平的影响[J].抗感染药学,2018,15(4):724-726. DOI:10.13493/j.issn.1672-7878.2018.04-071.

[13]穆金姬,张蕊荣.益生菌干预对重症急性胰腺炎患者炎性因子及胃肠道粘膜屏障功能的影响[J].贵州医药,2022,46(9):1406-1408. DOI:10.3969/j.issn.1000-744X.2022.09.036.

[14]刘幸,李海雯,黄红丽,等.益生菌强化肠内营养支持对重症急性胰腺炎患者胃肠道功能和炎症因子的影响[J].昆明医科大学学报,2021,42(11):81-86. DOI: 10.12259/j.issn.2095-610X.S20211116.

[15]蒋欢,蒋丽琳,张凯,等.早期肠内营养联合双歧杆菌三联活菌胶囊治疗重症急性胰腺炎的疗效及对炎性因子、肠黏膜屏障功能保护的影响[J].海南医学院学报,2015,21(11):1496-1498. DOI:10.13210/j.cnki.jhmu.20150729.002.

[16]邵永春,岳玉桃,李静,等.益生菌强化肠内营养支持对重症急性胰腺炎患者炎症因子的影响[J].黑龙江医药科学, 2022,45(1):113-114. DOI:10.3969/j.issn.1008-0104. 2022.01.045.

[17]肖剑辉,刘作良,王琴,等.早期肠内营养联合微生态制剂对重症急性胰腺炎患者的临床疗效及其对免疫功能的影响[J].中国微生态学杂志, 2022, 34(2): 195-200. DOI: 10.13381/j.cnki.cjm.202202013.

[18]俞灿,梁兴,梁艳.早期肠内营养联合双歧杆菌四联活菌素治疗重症急性胰腺炎疗效分析[J].中国医药科学, 2019, 9(3):251-254. DOI: 10.3969/j.issn.2095-0616. 2019.03.074.

[19]刘学进,陈垦.双歧杆菌三联活菌胶囊联合肠内营养治疗急性重症胰腺炎的临床观察[J].安徽医药, 2018, 22(10): 2008-2010. DOI: 10.3969/j.issn.1009-6469.2018.10.044.

[20]顾慧媛,高欣,钱丽娟,等.益生菌联合早期肠内营养治疗对重症急性胰腺炎患者血清炎性因子、肠黏膜屏障功能的影响[J].海南医学, 2017,28(23):3793-3795. DOI: 10.3969/j.issn.1003-6350.2017.23.003.

[21]赵碎巧.益生菌联合谷氨酰胺肠内营养用于重症急性胰腺炎的效果评价[J].现代中西医结合杂志, 2016, 25(22): 2459-2461. DOI: 10.3969/j.issn.1008-8849.2016.22.

[22]柴小兵,罗金键.三联活菌散在辅助治疗重症急性胰腺炎中的疗效观察[J].解放军医学院学报, 2016, 37(9): 967-969. DOI: 10.3969/j.issn.2095-5227.2016.09.013.

[23]石屏屏,吴玲云,王建军.双歧杆菌三联活菌胶囊对重症急性胰腺炎患者炎症因子及肠黏膜屏障功能的影响[J].海南医学院学报, 2015, 21(11): 1489-1491. DOI: 10.13210/j.cnki.jhmu.20150811.007.

[24]石金河,牛丽丹,杨飞云,等.早期肠内营养联合双歧杆菌三联活菌胶囊治疗重症急性胰腺炎疗效分析[J].新乡医学院学报,2015,32(1):48-50. DOI:10.7683/xxyxyxb. 2015.01.013.

[25]黄强业,粱开坚,王齐全,等.肠内营养+双歧杆菌三联活菌散对重症急性胰腺炎患者疗效的影响[J].现代消化及介入诊疗,2015,20(6):663-665. DOI: 10.3969/j.issn.1672-2159. 2015.06.035.

[26]崔东方,张端阳.双歧杆菌三联活菌胶囊联合肠内营养治疗急性重症胰腺炎的临床观察[J].中国民间疗法, 2019, 27(14): 90-91. DOI: 10.19621/j.cnki.11-3555/r.2019.1444.

[27]荣爱梅.双歧杆菌三联活菌胶囊辅助治疗重症急性胰腺炎效果分析[J].实用中西医结合临床, 2019, 19(11): 22-24. DOI: 10.13638/j.issn.1671-4040.2019.11.010.

[28]王迎芝,张先进,杨士彦.益生菌结合早期肠内营养对重症急性胰腺炎患者营养状况、肠黏膜屏障功能及肠内营养耐受性的影响[J/OL].中华消化病与影像杂志(电子版), 2023, 13(1):55-58 [2024-11-25]. https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0EhN6aHhoYnl5eHp6MjAyMzAxMDExGggxYzl2aGh4Mg%3D%3D. DOI: 10.3877/cma.j.issn.2095-2015.2023.01.011.

[29]Xu F, Hu X, Li SL. Value of serum CRP and IL-6 Assays combined with pancreatitis activity scoring system for assessing the severity of patients with acute pancreatitis[J]. Pak J Med Sci, 2024, 40(1Part-I): 145-149. DOI: 10.12669/pjms.40.1.7550

[30]高美玲,王小梅. RDW、NLR、hs-CRP检测对急性胰腺炎严重程度的评估价值[J].临床荟萃,2020,35(8):724-726. DOI:10.3969/j.issn.1004-583X.2020.08.011.

[31]Fitzpatrick E R. Acute responses to infectious and inflammatory disorders of the gastrointestinal system[J]. AACN Adv Crit Care, 2022, 33(1): 85-98. DOI: 10.4037/aacnacc2022486.

[32]Ma Z, Xie W, Luo T, et al. Exosomes from TNF-α preconditioned human umbilical cord mesenchymal stromal cells inhibit the autophagy of acinar cells of severe acute pancreatitis via shuttling bioactive metabolites[J]. Cell Mol Life Sci, 2023, 80(9): 257. DOI: 10.1007/s00018-023-04861-1.

[33]Malheiro F, Ângelo-Dias M, Lopes T, et al. Cytokine dynamics in acute pancreatitis: the quest for biomarkers from acute disease to disease resolution [J]. J Clin Med, 2024, 13(8): 2287. DOI: 10.3390/jcm13082287.

[34]Cheng R, Wang J, Wu Q, et al. The predictive value of serum DAO, HDC, and MMP8 for the gastrointestinal injury in the early stage of acute pancreatitis in an animal model and a clinical study[J]. Int J Gen Med, 2024, 17: 1937-1948. DOI: 10.2147/IJGM.S461352

[35]薛静,李胜,谢文贤,等.益生菌联合早期肠内营养治疗重症急性胰腺炎临床疗效的Meta分析[J].中国微生态学杂志, 2021,33(12):1413-1419. DOI: 10.13381/j.cnki.cjm.202112009.

[36]Huang J. Efficacy and safety of early enteral and intravenous fluid resuscitation in severe acute pancreatitis: a systematic review and meta-analysis[J]. Int J Colorectal Dis, 2023, 38(1): 122. DOI: 10.1007/s00384-023-04422-9.